Northwest Bio wins Swiss approval for cancer vaccine

(Reuters) - A spokesperson for the firm said the approval had come much earlier than had been expected at the time of the AIM float last month.




Shares in Northwest were seen trading up 9.76 percent by 0703 GMT at 112.5 pence.


Read more at Reuters.com Hot Stocks News